VivoSeq
Neurology

Narcolepsy Type 1

4

Pipeline Programs↗

4

Active Trials↗

3

Companies Involved↗

Narcolepsy Type 1 is an early-stage landscape with 4 programs across 3 companies. The most active players are Takeda, Eli Lilly, Centessa Pharmaceuticals (UK) Limited. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

29/100

Pipeline Velocity

19/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Takeda logo

Takeda

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 3C

Centessa Pharmaceuticals (UK) Limited

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

4

clinical trials

Recruiting4 · 100%

Clinical Trials

Trial Activity

A Randomized, Double-blind, 3-Arm Parallel Design Study to Investigate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Cleminorexton Compared With Placebo in Participants With Central Disorders of Hypersomnolence
Recruiting·CCentessa Pharmaceuticals (UK) Limited·Preclinical·NCT07598708·222 enrolled
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 Study 304)
Recruiting·AAlkermes, Inc.·Phase 3·NCT07540897·150 enrolled
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 Study 302)
Recruiting·AAlkermes, Inc.·Phase 3·NCT07455383·150 enrolled
A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 for the Treatment of Narcolepsy With Cataplexy (Narcolepsy Type 1)
Recruiting·Takeda logoTakeda·Phase 2·NCT07633301·92 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)